Alembic Pharmaceuticals Ltd. (APLLTD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 807696, "name": "Alembic Pharma", "stock_name": "Alembic Pharma", "full_name": "Alembic Pharmaceuticals Ltd.", "name_url": "stocks-analysis/alembic-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "831.35", "chg": 1.25, "chgp": "0.15%", "dir": 1, "prev_price": "830.10", "mcapval": "16,341.28 Cr", "mcap": "Small Cap", "scripcode": 533573, "symbol": "APLLTD", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE901L01018", "curr_date": "Aug 10, 03:55 PM", "curr_time": "16:12 PM", "last_traded_at": "Aug 10, 03:55 PM IST", "bse_nse_vol": "88.87 k", "exc_status": "Active", "traded_date": "Aug 10, 2026", "traded_date_str": "2026 08 10", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alembic-pharma-807696-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Alembic Pharmaceuticals Gains 4.09%: 3 Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-gains-409-3-key-factors-driving-the-weeks-momentum-4143379", "imagepath": "", "date": "2026-08-08 15:07:11", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>3 Aug:</strong> Stock opens at ₹806.10, up 1.14% on strong volume</p>\n <p><strong>4 Aug:</strong> Q1 FY27 results reveal strong revenue growth amid margin concerns</p>\n <p><strong>6 Aug:</strong> Valuation upgrade signals renewed price attractiveness; stock hits weekly high ₹834.60 (+2.27%)</p>\n <p><strong>7 Aug:</strong> Technical momentum shifts amid mixed signals; stock closes at ₹829.65 (-0.59%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.797.05</div></div>\n <div class=\"s..." }, { "title": "Alembic Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4140998", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AlembicPharmace_technicaldot_4140998.png", "date": "2026-08-07 08:04:08", "description": "Alembic Pharmaceuticals Ltd. has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a 2.27% gain on 7 Aug 2026, the stock remains under pressure from mixed monthly trends, prompting a cautious outlook for investors in this small-cap pharmaceutical player." }, { "title": "Alembic Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-4139065", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AlembicPharmace_valuationdot_4139065.png", "date": "2026-08-06 08:01:22", "description": "Alembic Pharmaceuticals Ltd. has recently undergone a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid a challenging pharmaceutical sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling investment case relative to peers and historical averages." }, { "title": "Are Alembic Pharmaceuticals Ltd. latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-alembic-pharmaceuticals-ltd-latest-results-good-or-bad-4138464", "imagepath": "", "date": "2026-08-05 19:24:18", "description": "Alembic Pharmaceuticals Ltd. has reported its financial results for Q1 FY27, revealing a complex operational landscape. The company achieved net sales of ₹2,149.77 crores, marking a significant year-on-year growth of 25.66%, which indicates strong revenue momentum and successful market penetration. This performance is noteworthy as it represents the highest quarterly revenue in the company's history. However, the net profit for the same period was ₹173.07 crores, reflecting a year-on-year increase of 12.11%, but a sequential decline of 14.62% from the previous quarter. This decline raises concerns about the company's ability to manage costs effectively and convert revenue growth into profit.\n\nThe operating margin, excluding other income, stood at 15.44%, which improved from the previous quarter but remains below the level achieved a year ago. This suggests ongoing challenges related to margin stability, pot..." }, { "title": "Alembic Pharmaceuticals Q1 FY27: Strong Revenue Growth Masks Margin Volatility Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/alembic-pharmaceuticals-q1-fy27-strong-revenue-growth-masks-margin-volatility-concerns-4136259", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AlembicPharmace_quaterlyResult_4136259.png", "date": "2026-08-04 20:01:45", "description": "Alembic Pharmaceuticals Ltd. reported a mixed performance in Q1 FY27, with consolidated net profit standing at ₹173.07 crores, representing a sequential decline of 14.62% from Q4 FY26 but a year-on-year improvement of 12.11%. The Vadodara-based pharmaceutical manufacturer, with a market capitalisation of ₹15,928 crores, delivered robust top-line growth with net sales surging 25.66% year-on-year to ₹2,149.77 crores, marking the highest quarterly revenue in the company's recent history. However, the stock has struggled to gain investor confidence, declining 16.30% over the past year whilst the broader pharmaceuticals sector rallied 17.87%, resulting in a significant underperformance of 34.17 percentage points." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-4131104", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AlembicPharmace_mojoScore_4131104.png", "date": "2026-08-01 10:10:49", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-4131116", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AlembicPharmace_mojoScore_4131116.png", "date": "2026-08-01 10:10:49", "description": "Alembic Pharmaceuticals Ltd. is rated Sell by MarketsMOJO. This rating was last updated on 20 July 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 01 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Alembic Pharmaceuticals Declines 3.50%: Downgrade and Mixed Technical Signals Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-declines-350-downgrade-and-mixed-technical-signals-shape-the-week-4120660", "imagepath": "", "date": "2026-07-25 16:04:18", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>20 Jul:</strong> Stock opens strong at Rs.841.60 (+1.97%) despite Sensex flat</p>\n <p><strong>21 Jul:</strong> Downgrade to Sell by MarketsMOJO amid mixed financial and technical signals</p>\n <p><strong>22 Jul:</strong> Continued decline to Rs.813.45 (-2.39%) as market sentiment weakens</p>\n <p><strong>23 Jul:</strong> Stock hits weekly low at Rs.794.05 (-2.38%) with bearish technical momentum</p>\n <p><strong>24 Jul:</strong> Slight recovery to Rs.796.50 (+0.31%) despite Sensex decline</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=..." }, { "title": "Alembic Pharmaceuticals Downgraded to Sell Amid Mixed Financial and Technical Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4111980", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/AlembicPharmace_mojoScore_4111980.png", "date": "2026-07-21 08:44:36", "description": "Alembic Pharmaceuticals Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jul 2026. This decision follows a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some attractive valuation metrics, the downgrade reflects concerns over flat recent financial performance, deteriorating technical indicators, and subdued long-term growth prospects." } ], "total": 5317, "sid": "807696", "stock_news_url": "https://www.marketsmojo.com/news/alembic-pharmaceuticals-807696" }, "announcements": [ { "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled \"Alembic Pharmaceuticals receives USFDA Final Approval for Silodosin Capsules, 4 mg and 8 mg.\".", "source": "NSE", "caption": "Alembic Pharmaceuticals Limited - Press Release", "datetime": "26-Nov-2019" }, { "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 22, 2019, titled \"Alembic Pharmaceuticals receives USFDA Approvals \".", "source": "NSE", "caption": "Alembic Pharmaceuticals Limited - Press Release", "datetime": "22-Nov-2019" }, { "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ( Listing Regulations, 2015 )", "source": "NSE", "caption": "Alembic Pharmaceuticals Limited - Other General Purpose", "datetime": "14-Nov-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Alembic Pharmaceuticals Ltd. has declared <strong>600%</strong> dividend, ex-date: 29 Jul 26", "dt": "2026-07-29", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

20 Jul: Stock opens strong at Rs.841.60 (+1.97%) despite Sensex flat

21 Jul: Downgrade to Sell by MarketsMOJO amid mixed financial and technical signals

22 Jul: Continued decline to Rs.813.45 (-2.39%) as market sentiment weakens

23 Jul: Stock hits weekly low at Rs.794.05 (-2.38%) with bearish technical momentum

24 Jul: Slight recovery to Rs.796.50 (+0.31%) despite Sensex decline

Read full news article

Alembic Pharmaceuticals Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-07-21 08:44:36

Alembic Pharmaceuticals Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jul 2026. This decision follows a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some attractive valuation metrics, the downgrade reflects concerns over flat recent financial performance, deteriorating technical indicators, and subdued long-term growth prospects.

Read full news article